Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients

ConclusionsTrastuzumab cardiotoxicity seems to accumulate among patients with underlying cardiac conditions. EF monitoring could be targeted to risk groups without compromising of the cardiac health or survival of HER2-positive breast cancer patients.

Source: Journal of Cancer Research and Clinical Oncology - June 5, 2018 Category: Cancer & Oncology Source Type: research